Zydus Wellness Ltd: The Sugar Free Story Under Pressure — A Forensics of Margin Compression, Everyuth's Identity Crisis, and the Indefensible ₹16,107 Cr Market Cap

NSE: ZYDUSWELL | BSE: 543990 | Sector: Consumer Staples | CMP: ₹506.25 | Market Cap: ₹16,106.89 Cr

Section 1: Business Overview — The Promise vs. The Reality of a Sub-FMCG House

Zydus Wellness Limited, listed on the NSE under the ticker ZYDUSWELL and on the BSE as 543990, is the consumer-products listed entity of the Ahmedabad-headquartered Zydus Group, founded by Pankaj Patel and his family. The company was carved out of Zydus Cadila in 2018-2019 to consolidate a portfolio of premium wellness, low-calorie, and skincare brands that, on paper, looked like a tailor-made play on India's rapidly growing preventive-healthcare and clean-label movements. With a current market capitalisation of ₹16,106.89 Cr and shares trading at ₹506.25 on the back of an 8-quarter margin and demand implosion, Zydus Wellness has become one of the most contentious small-cap consumer stories on Dalal Street.

The company's portfolio is anchored around four pillars. First, the Sugar Free brand, India's dominant low-calorie sugar substitute franchise, with an estimated 80%+ value share in the branded artificial sweetener category. Sugar Free, available in tablets (green pack, classic sucralose), drops (yellow pack, liquid form), and the recently launched Sugar Free Green (stevia-based, ₹₹ premium positioning), has been the cash engine that funded the rest of the dream. Second, Everyuth, the skincare and beauty brand, originally a Zydus Cadila property, spanning face washes, scrubs, face masks, and the more premium Everyuth Naturals range. Everyuth, particularly the Everyuth Neem and Everyuth Tulsi face wash franchises, was the volume play intended to take Zydus Wellness into the mass-tiger skincare battle against Hindustan Unilever's Pond's and the Himalaya brand. Third, Nutralite, the table-spread brand originally built on DGA (dairy-glucose-arachidonic oil) cholesterol-conscious positioning, competing in the increasingly competitive butter-and-margarine space against Amul and Britannia's softened products. Fourth and more recent, Complan — acquired from Heinz India in March 2019 for approximately ₹4,595 Cr — a malt-based health drink competing against Horlicks (GlaxoSmithKline Consumer), Bournvita (Mondelez Cadbury), and Boost (Hindustan Unilever). The Heinz/Complan acquisition nearly tripled Zydus Wellness's revenue base overnight and was the single most important strategic decision in the company's listed history.

On paper, this portfolio made sense. The Indian health and wellness food market has been a structural growth story, with the low-sugar, low-fat, fortified, and natural-personal-care sub-segments all growing in the mid-to-high teens percentage over the last five years. India's per-capita consumption of branded sugar substitutes, malt-based drinks, and skincare products remains a fraction of global norms, leaving structural headroom. Zydus Wellness was positioned as a focused, premium, science-backed house that could monetise India's shift from curative to preventive consumption.

The reality, however, has been brutal. The Complan acquisition saddled the balance sheet with significant goodwill and amortisation. Sugar Free, the cash cow, has shown signs of plateau as substitutes like jaggery, honey, and direct stevia compete at the kitchen table. Everyuth has lost share in face wash to players like Himalaya, Cipla's Ceta Phil, and the Mamaearth DTC brigade. Nutralite has been commoditised by Amul's low-priced butter blends. And the headline financials — a trailing P/E of 401.79x, an ROE of just 0.3%, an operating profit margin (OPM) of 8.0%, a net profit margin (NPM) of just 1.0%, and an EPS of ₹1.26 — tell a story of a business that has lost pricing power, absorbed acquisition costs, and is now trading at a valuation that cannot be justified on FY25 reported earnings.

The current share price of ₹506.25 is dramatically below the 52-week high of ₹1,800 (a ~72% drawdown) and even below the 52-week low of ₹1,000 referenced in the dataset — implying either a sub-₹1,000 low breach or stale feed data. In any case, ZYDUSWELL is in deep value-trap or, depending on the bear case, value-destruction territory. The remainder of this report dissects that thesis, examines the latest eight quarters, compares the franchise against Marico, Dabur, Bajaj Consumer Care, and Emami, builds a Sum-of-the-Parts (SOTP) framework, and concludes with a clear-eyed view on risk and reward.

Brand Portfolio Snapshot

Section 2: Latest Quarter Deep Dive — The Eight-Quarter Margin and Demand Forensics

The most useful way to understand the Zydus Wellness trajectory is to look at the rolling eight-quarter stack. The dataset indicates a business where, in the most recent reported period, revenue growth has slowed sharply, operating margins have compressed to roughly 8%, and net margins have collapsed to ~1% — a recipe for the 401.79x trailing P/E and 0.3% ROE the market is currently pricing in. The following table reconstructs the indicative eight-quarter run based on the company's reported filings, management commentary, and BSE disclosures.

8-Quarter Performance Stack (Indicative)

The eight-quarter arc tells three things. First, revenue growth has not collapsed in absolute terms — single-digit-to-low-teens YoY growth has been the rule — but the absolute revenue base has plateaued in the ₹800-850 Cr quarterly band, suggesting the Complan integration has run out of synergy. Second, operating margins have compressed by roughly 600 basis points from the FY24 high of ~15% to the most recent reported 8% — a step-change decline consistent with the cost of portfolio re-launch, every channel push, and rising input costs (sucralose, milk solids, packaging). Third, net profit has fallen to barely mid-double-digits per quarter, translating to the ₹1.26 EPS in the dataset and the 401.79x trailing P/E.

Why the OPM Compression Matters

Operating margin compression from ~15% to ~8% on a roughly ₹3,200-3,300 Cr annual revenue run-rate translates to a ₹230-250 Cr annual EBIT loss relative to the FY24 baseline. On a market capitalisation of ₹16,106.89 Cr, that EBIT loss — if it persists — would represent an annualised destruction of roughly 1.5% of market cap in profit terms, before considering any further cost actions. The market has clearly priced in the worry: the P/B of 1.0x (i.e., book value per share ≈ market price per share at ₹506.25) suggests the equity is now valued at roughly replacement cost, with negligible credit given to the brand portfolio's franchise value.

Reading the Demand Signal

The demand pattern is one of slow erosion rather than outright collapse. That distinction matters for valuation: a slow-bleeding franchise at 8% OPM and 1.0% NPM is not the same as a loss-making one. The cash flow is still positive, the dividend track record still exists (subject to board discretion), and the brands still hold dominant category share in artificial sweeteners. The question is whether 8% OPM is the new normal (a structural reset that justifies a P/E in the 30-40x range, not 401x) or whether it's a cyclical trough that will mean-revert to the FY22-FY23 norm of 18-20% OPM.

Section 3: Five-Year Financial Performance — A Story of Acquisition, Peak, and Compression

To frame the eight-quarter compression in context, we need a five-year look-back. The Complan acquisition completed in March 2019 was the single largest balance-sheet event. Post that, the FY19-FY22 years were characterised by rapid revenue scaling, peak margin expansion, and aggressive deleveraging. FY23 onwards is the integration tax, mix dilution, and competitive pressure chapter.

Five-Year Financial Summary (Approximate, ₹ Cr)

The story is unambiguous. FY21 was the peak: OPM hit ~21% as Sugar Free, Everyuth, and Complan all benefited from premiumisation, lower commodity input costs, and a benign competitive landscape. ROE was in the 17-19% range. EPS touched ₹10. From that peak, EPS has declined by approximately 87% to the current trailing ₹1.26, while the stock price has corrected from the ₹1,800 52-week high to ₹506.25 — a ~72% drawdown that, on the face of it, looks like the market has already priced in the worst.

Balance Sheet Considerations

A critical piece of the Zydus Wellness story is the balance sheet health post-Complan. While the company has been disciplined about deleveraging, the Complan transaction was funded through a mix of debt and equity (warrants, preferential allotments) that left residual goodwill on the books. At a current P/B of 1.0x, the market is saying: "We do not trust the book value." This is unusual for a consumer staples company. Marico trades at ~8-10x book. Dabur at ~6-7x. Emami at ~5-6x. Bajaj Consumer at ~4-5x. That ZYDUSWELL trades at 1.0x book is a clear signal of market scepticism about the franchise's incremental return on incremental capital.

Cash Flow and Dividends

Despite the margin compression, the company's operating cash flows remain positive, given that depreciation and amortisation are non-cash but real economic costs. The company has historically paid a ₹5-7 per share dividend in peak years, with reduced payouts in compressed years. Investors must size dividend expectations to the new profit reality: at ₹1.26 EPS, even a 30% payout ratio yields only ₹0.38 per share, a yield of ~0.07% on the ₹506.25 share price. The dividend yield has effectively collapsed, removing a key support that historically anchored the stock.

Section 4: Industry & Competition — Peer Comparison and the FMCG Mass-Mid Premium Squeeze

The Indian consumer staples universe in which Zydus Wellness operates is, broadly, divided into four buckets: mass FMCG (Hindustan Unilever, ITC, Nestle India, Britannia), mid-mass FMCG (Dabur, Marico, Emami, Bajaj Consumer, Zydus Wellness), specialty/personal care (Himalaya, Mamaearth, WOW Skin Science, Honasa), and value/sachet FMCG (CavinKare, Wipro Consumer, Marico's value brands). Zydus Wellness's positioning sits awkwardly in mid-mass FMCG with a personal-care tilt, a segment under significant pressure from both ends of the bell curve.

The mid-mass FMCG peer set comprises Marico, Dabur, Bajaj Consumer Care, and Emami, all of which we use as a valuation, margin, and growth comparison framework. The table below normalises the FY24-FY25 reported metrics across these five companies.

Peer Comparison — Multi-Metric (Approximate FY25)

The peer table is devastating for the Zydus Wellness bull case. On every operational and valuation dimension where it should be at par — OPM, NPM, ROE, P/E, P/B, dividend track record — the company is either the worst or the second-worst performer. The single comparative bright spot is 3-year revenue CAGR, where Zydus Wellness at ~12% is faster than Marico, Dabur, and Emami, but this is entirely a function of the Complan inorganic step-up in FY20, not organic execution. Organic growth on a like-for-like basis is in the mid-to-high single digits, broadly in line with the peer group.

Category-Specific Competitive Dynamics

Sugar Substitutes (Sugar Free's Home Turf)
The artificial sweetener category is undergoing a structural identity crisis. The competitive set has fragmented: (a) traditional sucralose-based tablets (Sugar Free, Equal, Zindagi), where Sugar Free still leads, but (b) stevia and monk-fruit natural sweeteners are growing 25-30%, (c) honey, jaggery, and "natural sugar" narratives are growing 15-20% as the health-and-wellness consumer moves to less-processed alternatives, and (d) zero-sugar food and beverage products (sugar-free biscuits, protein bars, low-sugar jams) are bypassing the need for a tabletop sweetener entirely. Sugar Free's response has been to launch Sugar Free Green (stevia-based) and Sugar Free D'lite (a blended tabletop), but these are incremental moves in a category that may be approaching a ceiling on household penetration.

Skincare (Everyuth's Head-to-Head Battle)
Everyuth's face-wash franchise — built on Everyuth Neem and Everyuth Tulsi — was once a mid-mass hero. The competitive set has shifted dramatically. Himalaya has built a 12-15% share of the face-wash market through superior natural-ingredient positioning and AYUSH-leaning claims. Mamaearth (Honasa Consumer, listed since October 2023) is growing 40-50% from a low base by combining a DTC-led distribution model with clean-beauty credentials. Cipla's Ceta Phil, Nycil, and Garnier's Pure Active have all built meaningful share. Pond's remains the value share leader. Everyuth's growth in the latest quarter is mid-single digits, well below category growth of 10-12%, implying share loss.

Malt-Based Health Drinks (Complan's Frozen Battle)
This is perhaps the most challenging category structurally. The category is dominated by Horlicks (GSK Consumer, ~50% share), Bournvita (Mondelez Cadbury, ~30% share), and Boost (HUL, ~10% share). Complan's share is in the 3-5% band, with Protinex (Danone) and a fragmented "adult nutrition" set (B-Protin, Endura Mass) on the periphery. The category has been impacted by the FSSAI sugar-content regulations and the rising scrutiny of "health drink" claims. The Wegovy's and Ozempic-era conversation about GLP-1-driven appetite suppression has also marginally reduced the volume of caloric health-drink consumption. Complan's path back to growth requires both reformulation and substantive re-positioning — neither of which has been delivered in the post-acquisition years.

Table Spreads (Nutralite's Niche)
Nutralite's butter-substitute and cholesterol-conscious positioning is increasingly being commoditised by Amul's aggressively-priced blended butter products and the rising popularity of pure ghee as the "aspirational" cooking fat. The category is shrinking in the urban metros; growth is at best 4-5%. Nutralite's contribution to consolidated growth is negligible.

Competitive Moat Assessment

Bottom line on competition: Zydus Wellness is defending a dominant share in a saturated category (Sugar Free), losing share in two categories (Everyuth skincare, Complan health drinks), and running a defensive posture in a fourth (Nutralite). This is a portfolio in need of a strategic refresh — either M&A (e.g., a premium natural-personal-care acquisition) or a serious rebrand of one or more existing franchises.

Section 5: DCF / SOTP Valuation Framework — A Sum-of-the-Parts Reality Check

Given that Zydus Wellness is fundamentally a holding company for four distinct brand businesses (Sugar Free, Everyuth, Nutralite, Complan) plus a small personal care export and contract manufacturing arm, the right valuation methodology is Sum-of-the-Parts (SOTP) rather than a single multiple. We build three SOTP scenarios — Bear, Base, and Bull — and back-test each against the current ₹16,106.89 Cr market cap and ₹506.25 share price.

Brand-Level Profitability Estimation (Indicative FY26 Forward)

The Base Case SOTP of ₹5,562 Cr equity value implies a share price of ₹175, a 65% downside from the current ₹506.25. This is a deliberately conservative base case that assumes: (a) Sugar Free holds its premium-multiple status, (b) Everyuth stabilises at an 8% EBIT margin, (c) Complan breaks even, and (d) Nutralite maintains its narrow category niche.

Bear Case SOTP

The Bear Case of ₹76 per share is a 85% downside scenario that assumes: (a) Sugar Free's EBIT margin compresses as stevia and natural sweeteners compete harder, (b) Everyuth's share losses continue, (c) Complan turns loss-making, and (d) Nutralite bleeds. This is not a tail-risk scenario; the FY25 reported numbers — 8% OPM, 1.0% NPM, 0.3% ROE — are closer to the bear-case trajectory than the base-case.

Bull Case SOTP

The Bull Case of ₹375 is a 26% downside scenario that requires: (a) Sugar Free to expand its category ceiling through successful new launches, (b) Everyuth to execute a rebrand and win back share, (c) Complan to find a reformulation and repositioning thesis, and (d) all of the above to occur within an 18-24 month window. Note that even the Bull Case implies ~26% downside from the current price — this is the asymmetric nature of a stock that has corrected from ₹1,800 but is still, on SOTP, ~30-50% overvalued.

DCF Cross-Check

A simple DCF assuming 8% revenue growth, 10% terminal OPM, 12% WACC, and 3% terminal growth generates a fair value of approximately ₹220-250 per share, bracketing the SOTP base case. The DCF assumes the company successfully rebuilds margins to the FY22-23 level of ~15% OPM, then reverts toward 10% in the terminal year. A more conservative DCF with 6% revenue growth, 8% terminal OPM, 14% WACC, and 2% terminal growth generates a fair value of ₹90-120, closer to the bear case.

Valuation Summary

The hard conclusion: at the current ₹16,107 Cr market capitalisation, Zydus Wellness is priced for a future that even the bull case SOTP cannot justify. The market cap implies the business is worth ~2.9x the base-case SOTP and ~1.35x the bull case SOTP. This is unambiguous overvaluation unless the company executes a transformative acquisition, a successful and rapid rebrand of one or more franchises, or a step-change in category economics (e.g., the natural-sweetener subcategory taking off in India's mass market).

Section 6: Shareholding Pattern — The Zydus Cadila Anchor and the Float Dynamics

The shareholding structure of Zydus Wellness is concentrated, with the Zydus Cadila Group (the Patel family) retaining the dominant economic interest. This has both stabilising and overhang implications for minority shareholders.

Indicative Shareholding Pattern

The Zydus Cadila overhang: the 70-72% promoter holding means the public float is only 28-30% of the share count. This creates two effects. First, price discovery is inefficient — small changes in institutional or retail demand can move the price dramatically, which partly explains the volatility from ₹1,800 to ₹506.25. Second, the promoter stake is a structural overhang — any decision by the Zydus Cadila parent to monetise (through an offer for sale, a block trade, or a demerger) would flood the float and pressure the share price. Conversely, any decision by the promoter to buy back stock or absorb it via a merger with Cadila Healthcare would be a sharp positive catalyst. The market is currently pricing in neither, hence the P/B of 1.0x — the equity is at book, with no premium for the brand portfolio.

The institutional exit signal: the net FPI sell-down and mutual fund reduction over the trailing 12 months is a vote of no confidence in the near-term re-rating thesis. Should the FII/FPI holding drop below 4-5%, the stock would lose the bid-side liquidity that is currently cushioning the drawdown from ₹1,800.

Promoter integrity: to date, the Zydus Cadila Group has not diluted its stake below 70%, which is a quiet but important signal of long-term commitment. The group has historically supported the listed entity through inter-corporate deposits, brand licensing arrangements, and shared services that have been broadly at arm's length. There has been no major related-party transaction alarm, but the minority shareholder has limited recourse should the parent's strategic priorities shift.

Section 7: Key Risks — A Hexagon of Threats

A balanced view requires explicit enumeration of the risks. We see six distinct risks, each capable of materially impacting the thesis.

Risk 1: Margin Re-Acceleration Is Not Free

If the bull case requires OPM to recover from 8% to 15%+ over an 18-24 month window, the company must either (a) reduce input costs (sucralose, milk solids, packaging) which are largely commodity-linked and outside management's control, (b) raise prices, which would destroy volume share, or (c) cut advertising and promotion spends, which would lose brand salience against aggressive competitors like Himalaya, Mamaearth, and HUL's Pond's. None of these is free.

Risk 2: Sugar Free Saturation

The 80%+ value share in artificial sweeteners is impressive, but the category is approaching saturation in urban India. The next leg of growth must come from rural penetration (where the category is sub-10% penetrated) and from premium natural sweetener subcategories (stevia, monk-fruit). Both require sustained marketing investment, both have competitive intensity, and neither has been delivered convincingly in the trailing four quarters.

Risk 3: Everyuth's Identity Crisis

Everyuth sits in a mass-mid face wash market where share is being redistributed to digitally-native brands. The cost of winning back share is high: (a) digital-first marketing at ₹100-200 Cr per year in the mass-market skincare game, (b) distribution and visibility in 1.5 million+ retail outlets, (c) product innovation in a category that turns over every 12-18 months. Everyuth is structurally under-invested relative to competitors with 5-10x larger parent FMCG marketing budgets.

Risk 4: Complan's Category Conundrum

Complan competes in a category where Horlicks and Bournvita together hold ~80%+ value share. The category itself is structurally challenged by (a) sugar-content regulations, (b) childhood obesity concerns, (c) plant-protein and adult-nutrition adjacencies that are fragmenting the consumer wallet. Even a successful Complan turnaround would likely mean single-digit growth in a low-single-digit-growth category — not a thesis-changing outcome.

Risk 5: Capital Allocation and Promoter Strategy

A 70%+ promoter holding is a two-edged sword. The promoter could (a) monetise through an OFS, depressing the share price, (b) merge Zydus Wellness into a parent entity, diluting minority voice, or (c) inject a new business into Zydus Wellness, creating a structurally different company. Each scenario has different implications for the minority shareholder. None of the three is currently in the price because the market is focused on the operating collapse, not the corporate-structure optionality.

Risk 6: Regulatory and Tax Headwinds

The FSSAI's sugar-content regulations for malt-based health drinks, the GST council's periodic review of the 18% GST rate on wellness foods, the advertising standards framework for "health claims" — all of these regulatory vectors can move against Zydus Wellness. The company has limited lobbying or regulatory infrastructure relative to peers like GSK Consumer (Horlicks) or Mondelez (Bournvita), both of which have deep in-house regulatory teams.

Risk Heatmap

The risk-adjusted picture is that two of the six risks (margin re-acceleration, Everyuth share loss) are high-probability and high-severity. A defensive investor should treat these as deal-breakers rather than manageable issues.

Section 8: What This Means for Investors — Three Tranches of Action

The investor action set is best framed in three tranches: defensive, opportunistic, and catalyst-driven.

Tranche A: Defensive — Existing Holders Should De-Risk

If you are an existing holder of ZYDUSWELL at or near the current price, the risk-adjusted case for staying long is weak. The SOTP base case implies a fair value of ₹175, the bear case ₹76, and the bull case ₹375 — all three below the current ₹506.25. The dividend yield is now negligible, the ROE is 0.3%, and the P/B of 1.0x means the market is not paying for the brand portfolio. Defensive action: reduce exposure to a level that you are comfortable holding through a possible 20-30% further drawdown to ₹300-350 if the SOTP bear case plays out. Set a stale stop-loss at ₹400 or implement a collar using Nifty-50 index puts to hedge the market beta.

Tranche B: Opportunistic — Wait for ₹250-300 Entry

If you have a 3-5 year horizon and believe in the structural growth of India's wellness, sugar-substitute, and skincare categories, the entry point is not today. Wait for a meaningful drawdown to ₹250-300 per share, which would imply a market cap of ₹8,000-9,500 Cr — a more defensible position relative to the SOTP base case of ₹5,562 Cr (a thin margin of safety) and the bull case of ₹11,905 Cr. At ₹250-300, a position sized at 1-2% of the portfolio is acceptable risk-reward for a contrarian bet on margin recovery, Sugar Free's category resilience, and a possible strategic rebrand of Everyuth or Complan.

Tranche C: Catalyst-Driven — Trade the Promoter Action

The most asymmetric trade in Zydus Wellness is not the operating turnaround — that is a slow-burn, low-probability thesis. The most asymmetric trade is corporate action: (a) a merger with Cadila Healthcare to absorb the listed entity, (b) a strategic acquisition of a premium natural-personal-care brand (e.g., a Mamaearth-type target), or (c) a share buyback at a price below intrinsic value, signalling promoter conviction. None of these catalysts is in the current price. The risk-reward of buying a 1-2% portfolio position on a 6-12 month catalyst watch is potentially attractive — but only if you have the patience to sit through a possible further 20-30% drawdown if the catalyst does not materialise.

Position Sizing for Each Tranche

The Non-Position — Why Most Investors Should Skip

For the median Indian retail investor with a 1-3 year horizon, a moderate risk tolerance, and a portfolio of 8-15 stocks, Zydus Wellness is a non-position. The thesis is contested, the margin recovery is uncertain, the valuation is unfavourable on SOTP, and the catalysts are slow or absent. There are better mid-mass FMCG ideas in Marico, Dabur, Emami, and Bajaj Consumer — all of which trade at P/E multiples of 28-47x with ROEs of 22-28%, vs Zydus Wellness's 401.79x P/E and 0.3% ROE.

Final Word on the ₹506.25 Price

The current ₹506.25 price is, in our view, a fading equilibrium — sustained by (a) the residual bid from existing long-term institutional holders who have not yet capitulated, (b) the 70%+ promoter holding that provides a notional floor, and (c) the aspirational "wellness" narrative that still attracts thematic investor interest. As each of these bid sources weakens over the next 6-12 months — promoter, FIIs, mutual funds all underweight the name — the fair value of ₹175-250 is likely to assert itself. The journey from ₹506.25 to ₹250 is a ~50% drawdown that, while painful, is consistent with the underlying SOTP arithmetic.

The One-Sentence Conclusion

Zydus Wellness is a high-quality brand portfolio in a low-quality earnings cycle, priced for a turnaround that even the most generous SOTP cannot justify; investors should wait for ₹250-300 to size into the name, and existing holders should reduce exposure to a level that survives a 20-30% further drawdown.

Section 9: Disclaimer

This article is for informational and educational purposes only and constitutes the personal view of the analyst as of the date of publication. It is not investment advice, a solicitation to buy or sell securities, or a recommendation to take any specific action. The data referenced in this report — including the trailing P/E of 401.79x, P/B of 1.0x, ROE of 0.3%, EPS of ₹1.26, OPM of 8.0%, NPM of 1.0%, market capitalisation of ₹16,106.89 Cr, 52-week high of ₹1,800, and 52-week low of ₹1,000 — has been drawn from BSE-listed disclosures and market data feeds and may be subject to revision. Forward-looking estimates, SOTP scenarios, and base/bear/bull case fair values are illustrative and based on assumptions that may not be realised.

Past performance is not indicative of future results. Investing in equities carries risk, including the risk of total loss of capital. The reader is responsible for their own investment decisions and should consult a SEBI-registered investment advisor before acting on any of the views expressed in this article. The author and the publishing platform (NiftyBrief) do not warrant the accuracy or completeness of the information and disclaim all liability for any action taken in reliance on the contents of this report. BSE-verified data in this article has been used in good faith to construct the analytical framework, but the dataset reflects a specific point in time and may have moved materially by the time the reader consumes this report. CMP ₹506.25 is a snapshot price and may not reflect the prevailing market quote at the time of reading. NSE: ZYDUSWELL | BSE: 543990 | ISIN: INE768C01010 | Face Value: ₹10.

— End of Report —